• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Enzalutamide increases survival in metastatic castration-resistant prostate cancer

bys25qthea
September 28, 2012
in Chronic Disease, Oncology
Reading Time: 4 mins read
0
Share on FacebookShare on Twitter

Image: CC

Key study points:

1.      Signaling through the androgen receptor plays a key role in the progression of prostate cancer including “castration-resistant” prostate cancer

2.      Enzalutamide, an inhibitor of the androgen-receptor signaling pathway, has a significant survival benefit for patients with metastatic castration-resistant prostate cancer

Primer: Prostate cancer is the second most common cancer in men worldwide. There is a wide spectrum of disease that ranges from microscopic, clinically insignificant disease to highly morbid, metastatic disease that leads to death. Given the broad spectrum of disease, the appropriate management and treatment of prostate cancer is primarily based upon risk stratification, especially with consideration of clinical staging. For example, clinically localized disease can generally be treated with radiation therapy or radical prostatectomy.

With metastatic disease, the standard treatment is androgen deprivation therapy (ADT) via surgical or medical orchiectomy because prostate cancer is dependent on androgen signaling for growth. Patients who progress despite ADT are thought to have castration-resistant prostate cancer, which was traditionally thought to be resistant to hormonal therapies. The chemotherapeutic option for these patients is taxane chemotherapy (e.g. docetaxel). Recently, an array of new therapies has been shown to be effective in these patients with metastatic castration-resistant prostate cancer, namely Sipuleucel-T (immunotherapy), abiraterone and cabazitaxel plus prednisone (see background reading).

Enzalutamide is an agent that inhibits nuclear translocation of the androgen receptor, DNA binding and co-activator recruitment. As it has been shown in phase 1 and phase 2 trials to have significant antitumor activity, this trial was designed to test its effectiveness for patients with metastatic castration-resistant prostate cancer.

RELATED REPORTS

Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force

RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection

Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States

Background reading:

1.      Courtney KD, Taplin ME. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer. Curr Opin Oncol. 2012;24(3):272-7.
2.      de Bono JS et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
3.      de Bono JS et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010;376:1147-54.
 

This [phase 3, randomized controlled] study: 1199 patients were randomly assigned in a 2:1 ratio to receive enzalutamide or a placebo treatment. Patients were eligible for the study with confirmed diagnosis of prostate cancer, castrate levels of testosterone, prior docetaxel therapy, and progressive disease defined by predetermined criteria. The primary end point was overall survival, while secondary end points included PSA levels, quality of life, time to PSA or radiographic progression, and time to adverse skeletal events.

The study was terminated after an interim analysis after 520 deaths. The median survival among the enzalutamide group and placebo group was 18.4 months and 13.6 months, respectively. Enzalutamide resulted in a 37% reduction in the risk of death compared to placebo (p<0.001). The superiority of enzalutamide was seen in all secondary end points (p<0.001). The rate of adverse events for patients in the enzalutamide group was comparable to the placebo group; the most common side effects for enzalutamide patients were fatigue, diarrhea and hot flashes. Of note, five patients in the enzalutamide group had seizures compared to none in placebo

In sum: Recent studies including this trial have discounted the previously-held notion that castrate-resistant patients had prostate cancer independent of androgen pathway activity. Enzalutamide acts as an inhibitor on the androgen-receptor signaling pathway, and the results of this well-designed phase 3 randomized controlled study convincingly indicates its effectiveness. Reinforcing this notion, the drug showed statistically significant improvement relative to placebo in the primary end point as well as all secondary endpoints. Thus, enzalutamide should be considered as another viable treatment for metastatic castration-resistant prostate cancer along with taxane chemotherapy, Sipuleucel-T immunotherapy, abiraterone and cabazitaxel/prednisone. Since there are no studies comparing these therapies against each other, the appropriate choice for patients with metastatic castration-resistant prostate cancer should be tailored uniquely to each patient.

Looking forward, results are pending from a phase 3 trial enzalutamide in patients without prior history of docetaxel chemotherapy (patients in this trial had all had a history of docetaxel therapy), and there are ongoing clinical trials that are investigating the use of enzalutamide in earlier stages of prostate cancer.

Click to read the study in NEJM

Click to read an accompanying editorial in NEJM

By RR

© 2012 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. DISCLAIMER: Posts are not medical advice and are not intended as such. Please see a healthcare professional if you seek medical advice.

 

Previous Post

Gastric bypass surgery for the severely obese associated with higher diabetes remission versus nonsurgical controls

Next Post

High BMI in children is associated with known risk factors of cardiovascular disease

RelatedReports

Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial
Cardiology

Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force

June 24, 2022
RSV positivity associated with reduced serious bacterial infection risk [Classics Series]
Infectious Disease

RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection

June 24, 2022
Cardiovascular events in Kawasaki Disease not significantly elevated over controls
Chronic Disease

Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States

June 24, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Gastroenterology Classics

CT evaluation in pancreatitis strongly correlates with patient outcomes [Classics Series]

June 24, 2022
Next Post

High BMI in children is associated with known risk factors of cardiovascular disease

Repeated, brief behavioral counseling reduces drinking and hospitalizations among at-risk alcohol consumers

Classics Series, Landmark Trials in Medicine

The TRICC trial: Restrictive transfusion in intensive care does not increase mortality [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.